J Thorac Cardiovasc Surg 2007;133:972
© 2007 The American Association for Thoracic Surgery
Discussion
| The first 20% of the full text of this article appears below. |
Dr Vallieres
(Seattle, Wash). Dr Veronesi, thank you for this review and for sending me all the material way ahead of time. That was appreciated.
In this retrospective review covering 124 patients over a period of 7 years, I think you have convincingly shown that the presence of nodal metastasis in patients undergoing pulmonary metastasectomy carries a dismal prognosis, as others have previously suggested but generally with less numerous series. From your survival data, it appears that the role of pulmonary metastasectomy is probably limited to nonexistent in the presence of N2 disease. Your article brings 2 issues to discuss relating the role of nodal sampling or dissection: first, the staging issues, and second, the potential of any therapeutic issue of removing lymph nodes at the time of pulmonary metastasectomy.
First Id like you to address a few questions regarding the staging issue. Considering your data and a 0% 5-year survival in patients with N2 disease, what is your practice now? Do you recommend . . . [Full Text of this Article]
Related Article
-
Prognostic role of lymph node involvement in lung metastasectomy
- Giulia Veronesi, Francesco Petrella, Francesco Leo, Piergiorgio Solli, Patrick Maissoneuve, Domenico Galetta, Roberto Gasparri, Giuseppe Pelosi, Tommaso De Pas, and Lorenzo Spaggiari
J. Thorac. Cardiovasc. Surg. 2007 133: 967-972.
[Abstract]
[Full Text]
[PDF]
Copyright © 2007 by The American Association for Thoracic Surgery.